Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.

Melanoma research - 1 Oct 2014

Peters Solange, Bouchaab Hasna, Zimmerman Stefan, Bucher Maya, Gaide Olivier, Letovanec Igor, Homicsko Krisztian, Michielin Olivier

Abstract excerpt

BRAF inhibitory therapy is the mainstream treatment for BRAF mutant advanced melanoma. However vemurafenib, a type I mutant BRAF V600 inhibitor, induces an array of proliferative skin disorders from keratosis pilaris-like and keratoacanthoma-like lesions to locally aggressive cutaneous squamous c...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dacarbazine
Share to Indoles
Share to Ipilimumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to MAP Kinase Kinase Kinases

Share to MAP Kinase Signaling System

Share to Neoplasm Metastasis

Share to Sulfonamides

Share to Vemurafenib

Source

Identifiers

PMID: 25185693
DOI: 10.1097/CMR.0000000000000055

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25185693-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.PMID 25185693Read ↗

Dermatological approach to vemurafenib skin toxicity: a single centre experience.Semantic proximity Read ↗

Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.Semantic proximity Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read ↗

Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.Semantic proximity Read ↗

Human papillomavirus-negative epithelial proliferations resembling condylomata acuminata in a patient receiving vemurafenib for Stage IV melanoma.Semantic proximity Read ↗

Dermatologic adverse events associated with targeted therapies for melanoma.Semantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

[Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.